HLA-E and myeloid sarcoma: This defective immunomodulatory function might be due to the increased expression of HLA-E by T cells in MS, which binds to the inhibitory NK receptor NKG2A, thereby inhibiting the cytotoxicity of CD56bright NK cells [53].